Menu

Bodybuilders Take Breast Cancer Drug

Tamoxifen, an endocrine therapy for women with breast cancer, is found in a supplement marketed to bodybuilders.

Feb 17, 2014
Jef Akst

Tamoxifen pillsWIKIMEDIA, NCIFor decades, some bodybuilders who’ve taken steroids to help increase their muscle mass have illegally purchased the breast cancer drug tamoxifen to prevent breast enlargement. But according to new research from Liverpool John Moores University in the U.K., others may simply have bought the dietary supplement Esto Suppress, which was found to contain the drug in three out of four samples tested by the investigators, who published their results last week (February 13) as a letter in the British Medical Journal (BMJ).

“Since the 2000s, a growing number of off-the-shelf ‘food,’ ‘herbal,’ or ‘dietary’ ‘supplements’—aimed at gym goers and people wanting to lose weight or enhance their sex lives—have contained pharmacologically active substances,” the authors wrote. “Most users will be unaware that they are taking these substances.”

The amount of tamoxifen varied by sample, with one sample containing 3.8 mg per pill. The suggested dose of Esto Suppress is two pills per day; when the drug is prescribed for early-stage breast cancer, patients typically take 20 mg a day. The researchers noted, however, that their samples were purchased two years ago, and it is not known whether the supplement still contains tamoxifen.

“This research highlights the need for consumers to be aware when choosing their sports supplements,” a spokesman for the Medicines and Healthcare Products Regulatory Agency (MHRA) told HuffPost Lifestyle. “These products may claim to increase performance but can contain powerful ingredients which can have serious side-effects.”

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

Horizon Discovery introduces Myeloid DNA Reference Standard to support genetic testing of leukemia

Horizon Discovery introduces Myeloid DNA Reference Standard to support genetic testing of leukemia

Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, today announced the launch of its Myeloid DNA Reference Standard. The first-to-market large cell-line derived myeloid cancer reference standard designed enables faster, more reliable and more cost-effective assay validation, to support the market in bringing routine testing into practice.

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!